Prepare fPELA-fHb Eurostars application

Two companies, Norwegian Gentian AS and Swiss Bühlmann AG, will develop, validate and bring to the market the worlds' first diagnostic test for fecal samples that can run on automated clinical analyzers and uses a combination of 3 crucial markers to support diagnosis, exclusion and monitoring of a wide range of gastrointestinal diseases, including but not limited to Crohn's disease, Chronic Pancreatitis, Diabetes Mellitus, and pancreatic and colorectal cancer. Following the successful performance of the partners' joint fecal calprotectin test and stool extraction device, we have identified two new markers that will enhance the test and further strengthen our position in a highly competitive fecal diagnostic market. Both markers are backed by substantial clinical evidence and are well-established in the ELISA or POC format. Adaptation to open, turbidimetric platforms will be attractive because of low price, high throughput, and ease-of-use.